• Explore /
  • Poster
  • / A randomized phase 3 trial of thalidomide and prednisone (TP) as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): An updated analysis of the NCIC Clinical Trials Group MY10 trial.

A randomized phase 3 trial of thalidomide and prednisone (TP) as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): An updated analysis of the NCIC Clinical Trials Group MY10 trial.

Abstract Poster

Authors

null

Annette E. Hay

NCIC Clinical Trials Group, Kingston, ON, Canada

Annette E. Hay , Suzanne Trudel , Nizar J. Bahlis , Darrell White , Waleed Sabry , Andrew Belch , Tony J. Reiman , Jean Roy , Chaim Shustik , Michael J. Kovacs , Jonathan Sussman , Donna Ellen Reece , Martha Lacy , Ralph M. Meyer , Lois E. Shepherd , Kate Whelan , Liting Zhu , Judy-Anne W. Chapman , A. Keith Stewart

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT00049673

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 8591)

DOI

10.1200/jco.2014.32.15_suppl.8591

Abstract #

8591

Poster Bd #

278

Abstract Disclosures

Similar Posters

First Author: Sarah A. Holstein

First Author: Noopur S. Raje

First Author: Brittany K. Ragon

Poster

2013 ASCO Annual Meeting

Clinical outcomes after intensive VDT-PACE therapy for relapsed multiple myeloma.

Clinical outcomes after intensive VDT-PACE therapy for relapsed multiple myeloma.

First Author: Preet Paul Singh